Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Significant Growth in Short Interest

Aligos Therapeutics, Inc. (NASDAQ:ALGS) was the recipient of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 597,300 shares, an increase of 30.7% from the December 15th total of 457,100 shares. Approximately 22.4% of the shares of the company are short sold. Based on an average daily volume of 421,900 shares, the days-to-cover ratio is presently 1.4 days.

Institutional Investors Weigh In On Aligos Therapeutics

An institutional investor recently raised its position in Aligos Therapeutics stock. Armistice Capital LLC grew its holdings in Aligos Therapeutics, Inc. (NASDAQ:ALGS) by 5.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,256,410 shares of the company’s stock after purchasing an additional 363,000 shares during the period. Armistice Capital LLC owned approximately 9.29% of Aligos Therapeutics worth $2,540,000 at the end of the most recent quarter. 60.43% of the stock is owned by institutional investors.

Aligos Therapeutics Stock Up 5.6 %

Shares of ALGS stock opened at $31.73 on Thursday. The firm has a market cap of $113.85 million, a P/E ratio of -2.38 and a beta of 2.50. The company has a 50 day moving average of $29.86 and a 200-day moving average of $17.73. Aligos Therapeutics has a 12-month low of $6.76 and a 12-month high of $46.80.

Aligos Therapeutics (NASDAQ:ALGS) last released its earnings results on Wednesday, November 6th. The company reported ($3.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.15) by ($0.92). Aligos Therapeutics had a negative return on equity of 114.34% and a negative net margin of 1,283.19%. The firm had revenue of $1.27 million during the quarter, compared to analysts’ expectations of $1.00 million. During the same period in the prior year, the business earned ($10.25) earnings per share. As a group, equities analysts expect that Aligos Therapeutics will post -10.36 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $75.00 price target on shares of Aligos Therapeutics in a research report on Thursday, November 7th.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).